These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 19289382)

  • 21. Comparative analysis of autoantibodies targeting peptidylarginine deiminase type 4, mutated citrullinated vimentin and cyclic citrullinated peptides in rheumatoid arthritis: associations with cytokine profiles, clinical and genetic features.
    Reyes-Castillo Z; Palafox-Sánchez CA; Parra-Rojas I; Martínez-Bonilla GE; del Toro-Arreola S; Ramírez-Dueñas MG; Ocampo-Bermudes G; Muñoz-Valle JF
    Clin Exp Immunol; 2015 Nov; 182(2):119-31. PubMed ID: 26149185
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Antibodies to mutated citrullinated vimentin and some associated autoantibodies in juvenile idiopathic arthritis].
    Zhang L; Ru J; Jie X; Che G; Jin X; Li X
    Zhonghua Er Ke Za Zhi; 2015 Dec; 53(12):948-51. PubMed ID: 26887552
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Significance and diagnostic value of synovial fluid anti-cyclic citrullinated peptide antibody and anti-mutated citrullinated vimentin antibodies in patients with serum negative rheumatoid arthritis].
    Qu SJ; Ye H; Jia RL; Li ZG
    Beijing Da Xue Xue Bao Yi Xue Ban; 2016 Dec; 48(6):933-936. PubMed ID: 27987492
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical diagnostic significance of 14-3-3η protein, high-mobility group box-1, anti-cyclic citrullinated peptide antibodies, anti-mutated citrullinated vimentin antibodies and rheumatoid factor in rheumatoid arthritis.
    Huang J; Zeng T; Zhang X; Tian Y; Wu Y; Yu J; Pei Z; Liu Y; Hu T; Tan L
    Br J Biomed Sci; 2020 Jan; 77(1):19-23. PubMed ID: 31433746
    [No Abstract]   [Full Text] [Related]  

  • 25. Mutation and citrullination modifies vimentin to a novel autoantigen for rheumatoid arthritis.
    Bang H; Egerer K; Gauliard A; Lüthke K; Rudolph PE; Fredenhagen G; Berg W; Feist E; Burmester GR
    Arthritis Rheum; 2007 Aug; 56(8):2503-11. PubMed ID: 17665451
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The anti-mutated citrullinated vimentin response classifies patients with rheumatoid arthritis into broad and narrow responders.
    Engelmann R; Brandt J; Eggert M; Karberg K; Krause A; Neeck G; Mueller-Hilke B
    J Rheumatol; 2009 Dec; 36(12):2670-4. PubMed ID: 19884278
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The role of anti-mutated citrullinated vimentin antibodies in the diagnosis of early rheumatoid arthritis.
    Liu X; Jia R; Zhao J; Li Z
    J Rheumatol; 2009 Jun; 36(6):1136-42. PubMed ID: 19447936
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antibodies binding to citrullinated telopeptides of type I and type II collagens and to mutated citrullinated vimentin synergistically predict the development of seropositive rheumatoid arthritis.
    Koivula MK; Heliövaara M; Rissanen H; Palosuo T; Knekt P; Immonen H; Risteli J
    Ann Rheum Dis; 2012 Oct; 71(10):1666-70. PubMed ID: 22419777
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antibodies to citrullinated human fibrinogen (ACF) have diagnostic and prognostic value in early arthritis.
    Nielen MM; van der Horst AR; van Schaardenburg D; van der Horst-Bruinsma IE; van de Stadt RJ; Aarden L; Dijkmans BA; Hamann D
    Ann Rheum Dis; 2005 Aug; 64(8):1199-204. PubMed ID: 15640269
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Value of anti-mutated citrullinated vimentin antibodies in diagnosing rheumatoid arthritis.
    Sghiri R; Bouajina E; Bargaoui D; Harzallah L; Fredj HB; Sammoud S; Ghedira I
    Rheumatol Int; 2008 Nov; 29(1):59-62. PubMed ID: 18496693
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Carbamylated vimentin represents a relevant autoantigen in Latin American (Cuban) rheumatoid arthritis patients.
    Martínez G; Gómez JA; Bang H; Martínez-Gamboa L; Roggenbuck D; Burmester GR; Torres B; Prada D; Feist E
    Rheumatol Int; 2016 Jun; 36(6):781-91. PubMed ID: 27038800
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Anti-cyclic citrullinated peptide (anti-CCP) and anti-mutated citrullinated vimentin (anti-MCV) relation with extra-articular manifestations in rheumatoid arthritis.
    Gonzalez-Lopez L; Rocha-Muñoz AD; Ponce-Guarneros M; Flores-Chavez A; Salazar-Paramo M; Nava A; Cardona-Muñoz EG; Fajardo-Robledo NS; Zavaleta-Muñiz SA; Garcia-Cobian T; Gamez-Nava JI
    J Immunol Res; 2014; 2014():536050. PubMed ID: 24804270
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Association of anti-modified citrullinated vimentin with subclinical atherosclerosis in early rheumatoid arthritis compared with anti-cyclic citrullinated peptide.
    El-Barbary AM; Kassem EM; El-Sergany MA; Essa SA; Eltomey MA
    J Rheumatol; 2011 May; 38(5):828-34. PubMed ID: 21362765
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The autoantibody repertoire in periodontitis: a role in the induction of autoimmunity to citrullinated proteins in rheumatoid arthritis?
    de Pablo P; Dietrich T; Chapple IL; Milward M; Chowdhury M; Charles PJ; Buckley CD; Venables PJ
    Ann Rheum Dis; 2014 Mar; 73(3):580-6. PubMed ID: 23434568
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Diagnostic value of anti-MCV antibodies in differentiating early inflammatory arthritis.
    Damjanovska L; Thabet MM; Levarth EW; Stoeken-Rijsbergen G; van der Voort EI; Toes RE; Huizinga TW; van der Helm-van Mil AH
    Ann Rheum Dis; 2010 Apr; 69(4):730-2. PubMed ID: 19451136
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antibodies to mutated citrullinated vimentin for diagnosing rheumatoid arthritis in anti-CCP-negative patients and for monitoring infliximab therapy.
    Nicaise Roland P; Grootenboer Mignot S; Bruns A; Hurtado M; Palazzo E; Hayem G; Dieudé P; Meyer O; Chollet Martin S
    Arthritis Res Ther; 2008; 10(6):R142. PubMed ID: 19077182
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Anti-cyclic citrullinated peptide positivity in non-rheumatoid arthritis disease samples: citrulline-dependent or not?
    Vannini A; Cheung K; Fusconi M; Stammen-Vogelzangs J; Drenth JP; Dall'Aglio AC; Bianchi FB; Bakker-Jonges LE; van Venrooij WJ; Pruijn GJ; Zendman AJ
    Ann Rheum Dis; 2007 Apr; 66(4):511-6. PubMed ID: 16984940
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Autoantibodies to citrullinated fibrinogen compared with anti-MCV and anti-CCP2 antibodies in diagnosing rheumatoid arthritis at an early stage: data from the French ESPOIR cohort.
    Nicaise-Roland P; Nogueira L; Demattei C; de Chaisemartin L; Rincheval N; Cornillet M; Grootenboer-Mignot S; Dieudé P; Dougados M; Cantagrel A; Meyer O; Serre G; Chollet-Martin S
    Ann Rheum Dis; 2013 Mar; 72(3):357-62. PubMed ID: 22580581
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Anti-citrullinated protein antibodies in rheumatoid arthritis: as good as it gets?
    Szekanecz Z; Soós L; Szabó Z; Fekete A; Kapitány A; Végvári A; Sipka S; Szücs G; Szántó S; Lakos G
    Clin Rev Allergy Immunol; 2008 Feb; 34(1):26-31. PubMed ID: 18270854
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antibodies against mutated citrullinated vimentin are a better predictor of disease activity at 24 months in early rheumatoid arthritis than antibodies against cyclic citrullinated peptides.
    Innala L; Kokkonen H; Eriksson C; Jidell E; Berglin E; Dahlqvst SR
    J Rheumatol; 2008 Jun; 35(6):1002-8. PubMed ID: 18398946
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.